Armstrong Juggles Reformulating Primatene Mist, Pushing To Sell Existing Inventory
This article was originally published in The Tan Sheet
Executive Summary
Armstrong Pharmaceuticals plans to submit in the fourth quarter an NDA to FDA for an OTC asthma inhaler reformulated without chlorofluorocarbon as a propellant. The House Energy and Power Subcommittee proposes allowing the firm to sell its remaining inventory of CFC-containing Primatene Mist.
You may also be interested in...
Primatene Mist NDA Expected By July After FDA OKs OTC Asthma Inhaler Trial
Amphastar plans this month to begin what it expects to be its final study to support an NDA to relaunch Primatene Mist. If the results support accurate self-selection and usage of the product by consumers, Amphastar should be ready to re-submit the NDA during the current quarter.
Primatene Mist NDA Expected By July After FDA OKs OTC Asthma Inhaler Trial
Amphastar plans this month to begin what it expects to be its final study to support an NDA to relaunch Primatene Mist. If the results support accurate self-selection and usage of the product by consumers, Amphastar should be ready to re-submit the NDA during the current quarter.
Will Primatene Mist Inventory Ever Leave The Warehouse?
Amphastar has inventory for the emergency asthma product but is frustrated by the recent second complete response letter from US FDA seeking additional information. Human factors issued figured into CRLs for both Primatene Mist and intranasal naloxone.